Chemspace | Covalent Modifiers for Analogs of Futibatinib

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Building Blocks for Analogs of Futibatinib

17 October 2022

Building Blocks for Analogs of Futibatinib

This September Futibatinib (LYTGOBI) received approval by the FDA as an oral drug for the treatment of cholangiocarcinoma (bile duct cancer).

It is a highly specific, potent, irreversible FGFR1–4 inhibitor which shows selective activity against tumors harboring various FGFR aberrations. Futibatinib has a warhead that unalterably binds to the target.

We offer you 40 Covalent Modifiers sets with versatile binders, which could be the perfect start for your research in anti-cancer medications and other fields!

Building Blocks for Analogs of Futibatinib

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in